We are proud to announce that the U.S. Department of Health and Human Services and the Cohen Foundation have selected Serimmune as a Phase 1 winner in the LymeX Diagnostics Prize, a LymeX Innovation Accelerator (LymeX) prize competition to accelerate the development of Lyme disease diagnostics. As a Phase 1 winner, we will receive $100,000 and an invitation to participate in a second phase.

The current two-tier serological testing system relies on the presence of antibodies and can only be used accurately four to six weeks after infection. The LymeX Diagnostics Prize’s open innovation model is accelerating discovery and development by offering no-strings-attached funding alongside exclusive access to key resources and collaboration opportunities—helping innovators take their solutions from concept to the healthcare market.

At the discretion of HHS and the Cohen Foundation, and subject to availability of future funding, at least one additional phase may follow Phase 2. Future phases are expected to focus on clinical and nonclinical validation of diagnostic tests that detect active infection by Lyme-disease-causing bacteria, as well as readiness for regulatory submission and market entry. Thanks to a $10 million pledge to the LymeX Diagnostics Prize from the Cohen Foundation, $9 million in additional LymeX prizes are projected to be available in proposed future phases.

Visit LymeXDiagnosticsPrize.com for more information and subscribe to the competition newsletter to receive future updates.

Press Release